Richter-Helm´s Biomanufacturing Facility Expansion progress: inauguration of the new office building

Richter-Helm BioLogics has reached a further and important construction milestone during the expansion of its production site in Bovenau. We officially and ceremoniously inaugurated the new office building on May 31, 2023 together with the mayor of Bovenau, Mr. Ambrock, two years after the groundbreaking ceremony.

“The new office building offers our employees a modern open-space workplace including an in-house canteen. Next week our employees will be able to move in and start their work.” said Dr. Pohlmeyer, Managing Director at Richter-Helm.

(source:  Richter-Helm intern, 2023)

With an invest of 95 million € Richter-Helm is going to triple the current production capacity by the installment of two additional highly flexible and fully equipped production trains with interchangeable product flows offering further capacities for late stage and commercial products. Bioreactor capacities of 300 litres and 1,500 litres will be added.

By mid of next year we will be able to start GMP-compliant production in the new site offering space for new clients and their pDNA and protein-based projects.

This might interest you

Biotechnologische Produktion ist unsere DNA

Die Richter-Helm Biologics GmbH & Co. KG aus Hamburg ist seit über 30 Jahren ein Lohnhersteller für biopharmazeutische Produkte. Mit großer Expertise im Bereich der DNA-Impfstoffe war das Unternehmen während der Pandemie für große US Entwicklungsunternehmen ein wichtiger Produktionspartner.
Mit neuen Produktionsanlagen will das Unternehmen jetzt seine Kapazitäten für die kommenden Jahre weiter ausbauen.

read more

A guide to the analysis of plasmid DNA

Plasmids are circular, double-stranded DNA molecules of various sizes originally found in bacteria, archaea and eukaryotic yeast. They replicate independently of chromosomal DNA and are easily genetically modified. Plasmids can be used for a variety of pharmaceutical purposes: as the active pharmaceutical ingredient (API) in DNA vaccines to prevent viral infections or cancer development; as critical raw material, starting material or ancillary material for viral vector production; or as template for mRNA-based products.

read more

Delivering flexible and transparent manufacturing processes

Developing and manufacturing microbial-derived biopharmaceutical products require deep expertise and reliable solutions that can guide a project to success while meeting evolving industry standards. To this end, pharmaceutical companies need expert partners capable of bringing promising cures to the market on time, regardless of scale.

read more